Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;47(5):446-450.
doi: 10.1111/cup.13648. Epub 2020 Jan 27.

Immunohistochemistry utilization in the diagnosis of melanoma

Matthew S Dinehart  1 , Scott M Dinehart  2 , Suporn Sukpraprut-Braaten  3 , Whitney A High  4
Affiliations

Immunohistochemistry utilization in the diagnosis of melanoma

Matthew S Dinehart et al. J Cutan Pathol. 2020 May.

Abstract

Background: The use of immunohistochemical (IHC) stains in dermatopathology is commonplace; however, little is known regarding utilization trends in melanoma diagnosis. Current Medicare local coverage determinations (LCDs) state that most pigmented lesions, including melanoma, can be diagnosed using H&E alone.

Methods: Histopathology reports for all biopsy-proven melanomas excised between January 1, 2017 and June 30, 2018, at a single dermatology clinic, were identified with the following parameters abstracted: laboratory/dermatopathologist rendering the diagnosis, whether IHC was performed, type/number of stains utilized, presence/depth of invasion, and melanoma subtype. The association of characteristics with IHC utilization was evaluated using χ2 test for categorical variables.

Results: Three hundred and fifty six eligible melanomas were identified. IHC was employed in 228 (64%) of the diagnoses. Invasive melanoma was diagnosed in 199 cases (55.9%) while 157 (44.1%) were identified as melanoma in situ (MIS). Of the 228 that utilized IHC, 117 were performed on invasive melanoma (58.8%) and 111 were performed on MIS (70.7%).

Conclusion: Our findings suggest a higher IHC usage for the diagnosis of melanoma than previously reported. Existing LCDs regarding IHC utilization in melanoma do not reflect the current state of practice. Further investigation regarding IHC utilization and the development of appropriate-use criteria for melanoma IHC is necessary.

Keywords: immunohistochemistry; local coverage determination; melanoma; utilization.

PubMed Disclaimer

References

REFERENCES

    1. Ordonez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol. 2014;45(2):191-205.
    1. CMS Website. Local Coverage Determination (LCD): Lab: Special Histochemical Stains and Immunohistochemical Stains (L3651, L3653, L35922, L36805). Available at: https://www.cms.gov/medicare-coverage-database/search/search-results.asp.... Accessed June 1, 2019.
    1. Zhao G, Lee KC, Kwon G, et al. The self-reported use of immunostains and cytogenetic testing in the diagnosis of melanoma by practicing U.S. pathologists of 10 selected states. J Cutan Pathol. 2016;43(6):492-497.
    1. Kim RH, Meehan SA. Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001-2015). J Cutan Pathol. 2017;44(3):221-227.
    1. Leong AS, Wright J. The contribution of immunohistochemical staining in tumour diagnosis. Histopathology. 1987;11(12):1295-1305.

LinkOut - more resources